摘要： 肝内胆管癌是一种起源于二级及以上胆管分支上皮细胞的恶性肿瘤,侵袭性强、预后差,目前的临床治疗效果仍不理想。近年来泛凋亡的研究日益增加,在肿瘤发生、发展中发挥重要作用。本文就泛凋亡及其在肝内胆管癌中的潜在作用进行综述,以期为肝内胆管癌的诊断和治疗提供新的研究方向。
周原世, 刘思淼, 杨宁. 泛凋亡在肝内胆管癌中的潜在作用[J]. 肝脏, 2026, 31(7): 939-944.
| [1] Qurashi M, Vithayathil M, Khan S A. Epidemiology of cholangiocarcinoma[J]. Eur J Surg Oncol, 2025, 51(2): 107064. [2] Tamandl D,Herberger B,Gruenberger B,et al. Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol 2008, 15(10): 2787-2794. [3] Bridgewater J,Fletcher P,Palmer D H,et al. Long-term outcomes and exploratory analyses of the randomized phase Ⅲ BILCAP Study[J]. J Clin Oncol, 2022, 40(18): 2048-2057. [4] Lee A J, Chun Y S. Intrahepatic cholangiocarcinoma: the AJCC/UICC 8th edition updates[J]. Chin Clin Oncol, 2018, 7(5): 52. [5] Wang H, Chen J, Zhang X, et al. Expert consensus on pathological diagnosis of intrahepatic cholangiocarcinoma (2022 version)[J]. J Clin Transl Hepatol, 2023, 11(7): 1553-1564. [6] Nagtegaal I D, Odze R D, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system[J]. Histopathology, 2020, 76(2): 182-188. [7] Aishima S, Oda Y. Pathogenesis and classification of intrahepatic cholangiocarcinoma: different characters of perihilar large duct type versus peripheral small duct type[J]. J Hepatobiliary Pancreat Sci, 2015, 22(2): 94-100. [8] Nepal C, O′Rourke C J , Oliveira D, et al. Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma[J]. Hepatology, 2018, 68(3): 949-963. [9] Lowery M A, Ptashkin R, Jordan E, et al. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention[J]. Clin Cancer Res, 2018, 24(17): 4154-4161. [10] Dong L Q, Lu D Y, Chen R, et al. Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma[J]. Cancer Cell. 2022, 40(1): 70-87. [11] Sia D, Hoshida Y, Villanueva, A, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes[J]. Gastroenterology, 2013, 144(4): 829-840. [12] Job S, Rapoud D, Santos A D, et al. Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma[J]. Hepatology, 2020, 72(3): 965-981. [13] Deng M J, Ran P, Chen L L, et al. Proteogenomic characterization of cholangiocarcinoma[J]. Hepatology, 2023, 77(2): 411-429. [14] Lin Y, Peng L, Zhao H, et al. Robust transcriptomic hallmarks targeting intratumor heterogeneity in intrahepatic cholangiocarcinoma[J]. Cell Rep Med, 2026. 7(4): 102708. [15] Martin-Serrano M, Kepecs B, Torres-Martin M, et al. Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications[J]. Gut, 2023, 72(4): 736-748. [16] Oh D Y, He A R, Bouattour, M, et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study[J]. Lancet Gastroenterol Hepatol, 2024, 9(8): 694-704. [17] Kelley R K, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2023, 401(10391): 1853-1865. [18] Abou-Alfa G K, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study[J]. Lancet Oncol, 2020, 21(5): 671-684. [19] Zhu A X, Macarulla T, Javle M M, et al. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial[J]. JAMA Oncol, 2021, 7(11): 1669-1677. [20] Javle M, Borad M J, Azad N S, et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multi-centre, open-label, phase 2a, multiple basket study[J]. Lancet Oncol, 2021, 22(9): 1290-1300. [21] Ohba A, Morizane C, Kawamoto Y, et al. Trastuzumab deruxtecan in human epidermal growth factor receptor 2-expressing biliary tract cancer (HERB; NCCH1805): a multicenter, single-arm, phase Ⅱ trial[J]. J Clin Oncol, 2024, 42(27): 3207-3217. [22] Harding J J, Fan J, Oh D Y, et al. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study[J]. Lancet Oncol, 2023, 24(7): 772-782. [23] Subbiah V S, Lassen U, Elez E, et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial[J]. Lancet Oncol, 2020, 21(9): 1234-1243. [24] Subbiah V, Wolf J, Konda B, et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial[J]. Lancet Oncol, 2022, 23(10): 1261-1273. [25] Kim J, Bradford D, Larkins E, et al. FDA approval summary: pralsetinib for the treatment of lung and thyroid cancers with RET gene mutations or fusions[J]. Clin Cancer Res, 2021, 27(20): 5452-5456. [26] Malireddi R S, Kesavardhana S, Kanneganti T D. ZBP1 and TAK1: master regulators of NLRP3 inflammasome/pyroptosis, apoptosis, and necroptosis (PAN-optosis)[J]. Front Cell Infect Microbiol, 2019, 9: 406. [27] Christgen S, Zheng M, Kesavardhana S, et al. Identification of the PANoptosome: a molecular platform triggering pyroptosis, apoptosis, and necroptosis (PANoptosis)[J]. Front Cell Infect Microbiol, 2020, 10: 237. [28] Lee S, Karki R, Wang Y, et al. AIM2 forms a complex with pyrin and ZBP1 to drive PANoptosis and host defence[J]. Nature, 2021, 597(7876): 415-419. [29] Malireddi R, Kesavardhana S, Karki R, et al. RIPK1 distinctly regulates yersinia-induced inflammatory cell death, PANoptosis[J]. Immunohorizons, 2020, 4(12): 789-796. [30] Sundaram B, Pandian N, Mall R, et al. NLRP12-PANoptosome activates PANoptosis and pathology in response to heme and PAMPs[J]. Cell, 2023, 186(13): 2783-2801.e20. [31] Sharma B R, Choudhury S M, Abdelaal H M, et al. Innate immune sensor NLRP3 drives PANoptosome formation and PANoptosis[J]. J Immunol, 2025, 214(6): 1236-1246. [32] Sundaram B, Pandian N, Kim H J, et al. NLRC5 senses NAD(+) depletion, forming a PANoptosome and driving PANoptosis and inflammation[J]. Cell, 2024, 187(15): 4061-4077.e17. [33] Chen B Y, Li L, Wang W Q, et al. Role of PANoptosis in cancer: double-edged sword effects and targeted therapies[J]. Int Immunopharmacol, 2026, 181: 116702. [34] Li Y, Zhang H, Liu J, et al. The molecular mechanisms, roles, and potential applications of PANoptosis in cancer treatment[J]. Front Immunol, 2025, 16: 1550800. [35] Wei S Y, Chen Z G, Ling X Y, et al. Comprehensive analysis illustrating the role of PANoptosis-related genes in lung cancer based on bioinformatic algorithms and experiments[J]. Front Pharmacol, 2023, 14: 1115221. [36] Lin J F, Hu P S, Wang Y Y, et al. Phosphorylated NFS1 weakens oxaliplatin-based chemosensitivity of colorectal cancer by preventing PANoptosis[J]. Signal Transduct Target Ther, 2022, 7(1): 54. [37] Liu L X, Heng J H, Deng D X, et al. Sulconazole induces PANoptosis by triggering oxidative stress and inhibiting glycolysis to increase radiosensitivity in esophageal cancer[J]. Mol Cell Proteomics, 2023, 22(6): 100551. [38] Pan H, Pan J, Li P, et al. Characterization of PANoptosis patterns predicts survival and immunotherapy response in gastric cancer[J]. Clin Immunol, 2022, 238: 109019. [39] Yu Y, You Y, Duan Y, et al. Multi-omics approaches for identifying the PANoptosis signature and prognostic model via a multimachine-learning computational framework for intrahepatic cholangiocarcinoma[J]. Hepatology, 2026;83(2): 466-483. |
| [1] | 杨肖颖, 杨娜. CT及MRI特征对多房样肝囊肿与肝黏液性囊性肿瘤的鉴别价值[J]. 肝脏, 2026, 31(7): 1010-1014. |
| [2] | 叶晓玲, 盛滋科, 庄焱, 谢青. 误诊为肝硬化的骨髓增殖性肿瘤1例并文献复习[J]. 肝脏, 2026, 31(7): 1055-1057. |
| [3] | 王语林, 纪元, 郭欣欣, 韩晶, 张欣. 肝内胆管癌穿刺标本组织学分型的免疫组化分类模型构建及诊断价值[J]. 肝脏, 2026, 31(6): 816-821. |
| [4] | 侯元凯, 王志恒, 曾骞, 周道祝. 钇-90微球内放射治疗肝内胆管癌的应用现状[J]. 肝脏, 2026, 31(6): 913-916. |
| [5] | 范斌, 黄胜利, 易钢锋, 周宇. 原发性肝癌患者肿瘤微环境中CD8+细胞毒性T淋巴细胞浸润水平与预后的关系探究[J]. 肝脏, 2026, 31(3): 369-374. |
| [6] | 朱泓宇, 胡庆超, 宋庆杰, 宋辉, 朱忠辉. 血清DKK1、TAP联合异常凝血酶原术前预测肝细胞癌微血管侵犯的价值[J]. 肝脏, 2026, 31(3): 385-389. |
| [7] | 张秀娟, 臧传诚, 邹红梅. 双能CT定量参数对肝细胞癌患者经动脉化疗栓塞术后不同组织类型的诊断价值[J]. 肝脏, 2026, 31(2): 224-227. |
| [8] | 谭江琦, 范芯铷, 王庆, 周华邦, 董立巍, 汪慧. 肝细胞癌辅助与新辅助治疗的最新进展:免疫治疗策略的前景与挑战[J]. 肝脏, 2026, 31(1): 2-5. |
| [9] | 蒋莉莉, 周苏康, 居烨. 阿帕替尼联合GEMOX方案对胆囊癌患者临床疗效及肿瘤标志物的影响[J]. 肝脏, 2026, 31(1): 127-131. |
| [10] | 范芯铷, 王庆, 周华邦, 汪慧. 免疫治疗时代晚期肝癌患者从客观缓解到长期生存的机遇与挑战[J]. 肝脏, 2025, 30(9): 1177-1179. |
| [11] | 王新帅, 李善宝, 徐军明. 肝移植在非标准肝脏恶性肿瘤中的应用突破与挑战[J]. 肝脏, 2025, 30(9): 1180-1182. |
| [12] | 刘苗, 张群青, 吴娟. 剪切波弹性成像参数及肝癌患者肿瘤标志物水平与病灶组织资料的关联度分析[J]. 肝脏, 2025, 30(9): 1234-1237. |
| [13] | 王海玉, 李波, 高敬涵, 童金龙. 肿瘤相关巨噬细胞在肝癌免疫治疗中的研究进展[J]. 肝脏, 2025, 30(9): 1287-1292. |
| [14] | 杨啸天, 张颖, 郑昕. 乙型肝炎病毒相关肝细胞癌复发的空间——免疫研究进展[J]. 肝脏, 2025, 30(8): 1023-1025. |
| [15] | 李壮, 刘勇, 朱峰. 肝切除术联合腹腔热灌注化疗对肝癌患者术后复发性肝癌的预后分析[J]. 肝脏, 2025, 30(7): 930-933. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
